Initial studies of the drug show that it will cure different genetic types of the virus, including the fourth type, which is pervasive in Egypt. The second phase includes total manufacturing of the drug after the transfer of the necessary technologies and experiences required for production. The company also aims to produce other drugs in Egypt and export them to African markets. For his part, Graeme Robertson, director of the company in Africa, said that the cure rate of the new drug is 98%. It would be used for patients who have not responded to the drugs currently used, noting that Egypt is the only African country that has the required potential and infrastructure to produce Hepatitis C drugs.

Source: Daily News Egypt May 18, 2017 15:00 UTC